Phase I/IIa trials of a novel T-cell epitope-based peptide therapy for peanut allergy

花生过敏影响约2%的人口，是食物引发的过敏性死亡的主要原因。花生过敏通常是终身的。目前没有具体的治疗方法。我们在屋尘螨和草免疫疗法的免疫学方面的丰富经验使我们能够确定作为安全疫苗所需的花生蛋白的关键成分，以建立对花生食品的耐受性。现在，我们将通过早期临床试验来开发这种新型和革命性的疫苗。

Peanut allergy affects ~2% of the population and is the major cause of food triggered deaths from anaphylaxis. Typically peanut allergy is lifelong. Currently there is no specific treatment. Our vast experience in immunology for house dust mite and grass immunotherapy allowed us to identify critical components of peanut proteins needed as a safe vaccine to build tolerance to peanut foods. Now we will progress this novel and revolutionary vaccine through early phase clinical trials.